Alina Basnet, MD, MBBS, SUNY Upstate Medical University, Syracuse, NY, discusses genomic differences in older vs younger patients with bladder cancer. The male preponderance was higher in the older age group and ancestry revealed vast ethnic differences between the two groups. MSI-high status was uncommon in both, only older subjects displayed a TMB +10, and PD-L1 was only observed in a small subset of patients. The study found that whilst mutations in ERBB2, ERBB3, FGFR3 and MTAP were higher in the older age group, the results were insignificant. Similarly, cyclin D1, HRS and PTEN mutations were higher, but insignificant, in younger patients. The findings are not prognostic or predictive of any therapies. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
